Loading clinical trials...
Loading clinical trials...
A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046
Conditions
Interventions
Upadacitinib
Locations
116
United States
University of Arkansas for Medical Sciences /ID# 221021
Little Rock, Arkansas, United States
Duplicate_First OC Dermatology Research Inc /ID# 218619
Fountain Valley, California, United States
UCSF Fresno /ID# 218453
Fresno, California, United States
California Allergy and Asthma Medical Group /ID# 218635
Los Angeles, California, United States
Dermatology Research Associates /ID# 218637
Los Angeles, California, United States
Dermatology Clinical Trials /ID# 218627
Newport Beach, California, United States
Start Date
January 15, 2020
Primary Completion Date
September 11, 2023
Completion Date
September 11, 2023
Last Updated
January 9, 2025
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions